Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.

Abstract

The highly variable toxicity of amonafide is primarily due to genetic differences in N-acetylation. Other genetic (race) and acquired factors (baseline WBC count and albumin level) also appear to influence the extent of toxicity observed following administration of this agent.